Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant, Ramosetron, and Dexamethasone for CINV in Ovarian Cancer
NCT01012336Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Samsung Medical Center. Started May 2010; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01012336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012336.